MVM was founded in 1997 and manages several funds. MVM's latest fund totals more than $200 million. MVM has a global perspective on healthcare and maintains offices in Boston and London.
MVM invests broadly across the healthcare sector, including biotechnology, specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, healthcare services, and digital health.
VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter Ventures.
Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.